3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
36
Neoplasms
8
HER2-positive Breast Cancer
4
Triple Negative Breast Neoplasms
3
Neoplasm Metastasis
3
Salivary Gland Neoplasms
2
Pathologic Complete Response
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Hematologic Neoplasms
2
HER2-positive Early Breast Cancer
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Lymphoproliferative Disorders
1
Lung Neoplasms
1
Liver Neoplasms
1
Hemangiosarcoma
1
Heart Failure
1
Interventions
pembrolizumab
8
Nivolumab
6
Ipilimumab
6
cemiplimab
4
aldesleukin
3
Interleukin-2
3
fludarabine
2
Specimen Handling
2
Niacinamide
2
HhAntag691
2
Cyclophosphamide
2
Blood Specimen Collection
2
Biopsy
2
trametinib
1
spartalizumab
1
sonidegib
1
pertuzumab
1
lifileucel
1
four-arm poly(ethylene oxide)-b-poly(2-(diethylamino)ethyl methacrylate)
1
fludarabine phosphate
1
dabrafenib
1
brodalumab
1
atezolizumab
1
Vitamin A
1
Trastuzumab
1
Tissue Banks
1
Surgical Procedures, Operative
1
Sunscreening Agents
1
Standard of Care
1
Second Harmonic Generation Microscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Skin Neoplasms
×
pertuzumab
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled